<?xml version="1.0" encoding="UTF-8"?>
<PubmedArticleSet xmlns:gate="http://www.gate.ac.uk" gate:gateId="0" gate:annotMaxId="373">
  <PubmedArticle gate:gateId="1"><MedlineCitation gate:gateId="2" Status="MEDLINE" Owner="NLM">
    <PMID gate:gateId="3" Version="1">20231034</PMID>
        <DateCreated gate:gateId="4">
            <Year gate:gateId="5">2010</Year>
            <Month gate:gateId="6">03</Month>
            <Day gate:gateId="7">29</Day></DateCreated>

        <DateCompleted gate:gateId="8">
            <Year gate:gateId="9">2010</Year>
            <Month gate:gateId="10">05</Month>
            <Day gate:gateId="11">11</Day></DateCompleted>

        <DateRevised gate:gateId="12">
            <Year gate:gateId="13">2010</Year>
            <Month gate:gateId="14">11</Month>
            <Day gate:gateId="15">18</Day></DateRevised>

        <Article gate:gateId="16" PubModel="Print-Electronic"><Abstract><AbstractText><condition>In low-risk </condition><population>patients</population> , the <group role="experiment" id="0">zotarolimus-eluting stent</group> has been shown to reduce rates of restenosis without increasing the risk of stent thrombosis. We compared the efficacy and safety of the <group role="experiment" id="0">zotarolimus-eluting stent</group> versus the <group role="control" id="1">sirolimus-eluting stent</group> in <population>patients</population> <condition>with coronary artery disease who were receiving routine clinical care with no direct follow-up</condition>.We did a single-blind, all-comer superiority trial in adult <population>patients</population> <condition>with chronic stable coronary artery disease or acute coronary syndromes</condition> , and <condition>at least one target lesion</condition>. <population>Patients</population> were treated at one of five percutaneous coronary intervention centres between January, 2006, and August, 2007. Computer-generated block randomisation and a telephone allocation service were used to randomly assign <population>patients</population> to receive the <group role="experiment" id="0">zotarolimus-eluting</group> or the <group role="control" id="1">sirolimus-eluting stent</group> . Data for follow-up were obtained from national Danish administrative and health-care registries. <short>The primary endpoint</short> was a composite of major adverse cardiac events within <outcome id="0" type="bad">The primary endpoint was a composite of major adverse cardiac events within <time id="0">9 months</time> : cardiac death, myocardial infarction, and target vessel revascularisation</outcome> . Intention-to-treat analyses were done at <time id="0" units="months">9-month</time> and <time id="1" units="months">18-month</time> follow-up. This trial is registered with ClinicalTrials.gov, number NCT00660478.<gs group="0">1162</gs> <population>patients</population> (1619 lesions) were assigned to receive the <group role="experiment" id="0">zotarolimus-eluting stent</group> , and <gs group="1">1170</gs> <population>patients</population> (1611 lesions) to receive the <group role="control" id="1">sirolimus-eluting stent</group> . 67 <population>patients</population> (72 lesions) had stent failure, and <lost group="1">six</lost> <population>patients</population> were lost to follow-up. All randomly assigned <population>patients</population> were included in analyses at <time id="0" units="months">9-month</time> follow-up; 2200 <population>patients</population> (94%) had completed <time id="1" units="months">18-month</time> follow-up by the time of our assessment. At <time id="0" units="months">9 months</time>, the <outcome id="0" type="bad">primary endpoint</outcome> had occurred in a higher proportion of <population>patients</population> treated with the <group role="experiment" id="0">zotarolimus-eluting stent</group> than in those treated with the <group role="control" id="1">sirolimus-eluting stent</group> ( <on time="0" outcome="0" group="0">72</on> [ <eventRate>6%</eventRate> ] vs <on time="0" outcome="0" group="1">34</on> [ <eventRate>3%</eventRate> ]; HR 2.15, 95% CI 1.43-3.23; p=0.0002). At <time id="1" units="months">18-month</time> follow-up, this difference was sustained ( <on time="1" outcome="0" group="0">113</on> [ <eventRate>10%</eventRate> ] vs <on time="1" outcome="0" group="1">53</on> [ <eventRate>5%</eventRate> ]; 2.19, 1.58-3.04; p&lt;0.0001). For <population>patients</population> receiving the <group role="experiment" id="0">zotarolimus-eluting stent</group> and those receiving the <group role="control" id="1">sirolimus-eluting stent</group> , <outcome id="1" type="bad">all cause-mortality</outcome> was similar at <time id="0" units="months">9-month</time> follow-up ( <on time="0" outcome="1" group="0">25</on> [ <eventRate>2%</eventRate> ] vs <on time="0" outcome="1" group="1">18</on> [ <eventRate>2%</eventRate> ]; 1.40, 0.76-2.56; p=0.28), but was significantly different at <time id="1" units="months">18-month</time> follow-up ( <on time="1" outcome="1" group="0">51</on> [ <eventRate>4%</eventRate> ] vs <on time="1" outcome="1" group="1">32</on> [ <eventRate>3%</eventRate> ]; 1.61, 1.03-2.50; p=0.035).The <group role="control" id="1">sirolimus-eluting stent</group> is superior to the <group role="experiment" id="0">zotarolimus-eluting stent</group> for <population>patients</population> <condition>receiving routine clinical care</condition>.Cordis and Medtronic.</AbstractText></Abstract></Article>


        <MedlineJournalInfo gate:gateId="154">
            <Country gate:gateId="155">England</Country>
            <MedlineTA gate:gateId="156">Lancet</MedlineTA>
            <NlmUniqueID gate:gateId="157">2985213R</NlmUniqueID>
            <ISSNLinking gate:gateId="158">0140-6736</ISSNLinking></MedlineJournalInfo>

        <ChemicalList gate:gateId="159">
            <Chemical gate:gateId="160">
                <RegistryNumber gate:gateId="161">0</RegistryNumber>
                <NameOfSubstance gate:gateId="162">zotarolimus</NameOfSubstance></Chemical>

            <Chemical gate:gateId="163">
                <RegistryNumber gate:gateId="164">53123-88-9</RegistryNumber>
                <NameOfSubstance gate:gateId="165">Sirolimus</NameOfSubstance></Chemical></ChemicalList>


        <CitationSubset gate:gateId="166">AIM</CitationSubset>
        <CitationSubset gate:gateId="167">IM</CitationSubset>
        <CommentsCorrectionsList gate:gateId="168">
            <CommentsCorrections gate:gateId="169" RefType="CommentIn">
                <RefSource gate:gateId="170">Lancet. 2010 Mar 27;375(9720):1060-2</RefSource>
                <PMID gate:gateId="171" Version="1">20231035</PMID></CommentsCorrections>

            <CommentsCorrections gate:gateId="172" RefType="CommentIn">
                <RefSource gate:gateId="173">Nat Rev Cardiol. 2010 May;7(5):240</RefSource>
                <PMID gate:gateId="174" Version="1">20425900</PMID></CommentsCorrections></CommentsCorrectionsList>


        <MeshHeadingList gate:gateId="175">
            <MeshHeading gate:gateId="176">
                <DescriptorName gate:gateId="177" MajorTopicYN="N">Aged</DescriptorName></MeshHeading>

            <MeshHeading gate:gateId="178">
                <DescriptorName gate:gateId="179" MajorTopicYN="N">Angioplasty, Balloon, Coronary</DescriptorName></MeshHeading>

            <MeshHeading gate:gateId="180">
                <DescriptorName gate:gateId="181" MajorTopicYN="N">Coronary Disease</DescriptorName>
                <QualifierName gate:gateId="182" MajorTopicYN="Y">therapy</QualifierName></MeshHeading>

            <MeshHeading gate:gateId="183">
                <DescriptorName gate:gateId="184" MajorTopicYN="N">Coronary Restenosis</DescriptorName>
                <QualifierName gate:gateId="185" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading>

            <MeshHeading gate:gateId="186">
                <DescriptorName gate:gateId="187" MajorTopicYN="Y">Drug-Eluting Stents</DescriptorName>
                <QualifierName gate:gateId="188" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading>

            <MeshHeading gate:gateId="189">
                <DescriptorName gate:gateId="190" MajorTopicYN="N">Female</DescriptorName></MeshHeading>

            <MeshHeading gate:gateId="191">
                <DescriptorName gate:gateId="192" MajorTopicYN="N">Humans</DescriptorName></MeshHeading>

            <MeshHeading gate:gateId="193">
                <DescriptorName gate:gateId="194" MajorTopicYN="N">Male</DescriptorName></MeshHeading>

            <MeshHeading gate:gateId="195">
                <DescriptorName gate:gateId="196" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading>

            <MeshHeading gate:gateId="197">
                <DescriptorName gate:gateId="198" MajorTopicYN="N">Myocardial Infarction</DescriptorName>
                <QualifierName gate:gateId="199" MajorTopicYN="N">etiology</QualifierName></MeshHeading>

            <MeshHeading gate:gateId="200">
                <DescriptorName gate:gateId="201" MajorTopicYN="N">Retreatment</DescriptorName></MeshHeading>

            <MeshHeading gate:gateId="202">
                <DescriptorName gate:gateId="203" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading>

            <MeshHeading gate:gateId="204">
                <DescriptorName gate:gateId="205" MajorTopicYN="N">Sirolimus</DescriptorName>
                <QualifierName gate:gateId="206" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName gate:gateId="207" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName></MeshHeading>

            <MeshHeading gate:gateId="208">
                <DescriptorName gate:gateId="209" MajorTopicYN="N">Thrombosis</DescriptorName>
                <QualifierName gate:gateId="210" MajorTopicYN="N">etiology</QualifierName></MeshHeading>

            <MeshHeading gate:gateId="211">
                <DescriptorName gate:gateId="212" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList>


        <InvestigatorList gate:gateId="213">
            <Investigator gate:gateId="214" ValidYN="Y">
                <LastName gate:gateId="215">Rasmussen</LastName>
                <ForeName gate:gateId="216">K</ForeName>
                <Initials gate:gateId="217">K</Initials></Investigator>

            <Investigator gate:gateId="218" ValidYN="Y">
                <LastName gate:gateId="219">Thygesen</LastName>
                <ForeName gate:gateId="220">K</ForeName>
                <Initials gate:gateId="221">K</Initials></Investigator>

            <Investigator gate:gateId="222" ValidYN="Y">
                <LastName gate:gateId="223">NÃ¸rgaard</LastName>
                <ForeName gate:gateId="224">B L</ForeName>
                <Initials gate:gateId="225">BL</Initials></Investigator>

            <Investigator gate:gateId="226" ValidYN="Y">
                <LastName gate:gateId="227">Terkelsen</LastName>
                <ForeName gate:gateId="228">C J</ForeName>
                <Initials gate:gateId="229">CJ</Initials></Investigator>

            <Investigator gate:gateId="230" ValidYN="Y">
                <LastName gate:gateId="231">Madsen</LastName>
                <ForeName gate:gateId="232">M</ForeName>
                <Initials gate:gateId="233">M</Initials></Investigator>

            <Investigator gate:gateId="234" ValidYN="Y">
                <LastName gate:gateId="235">Johnsen</LastName>
                <ForeName gate:gateId="236">S P</ForeName>
                <Initials gate:gateId="237">SP</Initials></Investigator>

            <Investigator gate:gateId="238" ValidYN="Y">
                <LastName gate:gateId="239">SÃ¸rensen</LastName>
                <ForeName gate:gateId="240">H T</ForeName>
                <Initials gate:gateId="241">HT</Initials></Investigator>

            <Investigator gate:gateId="242" ValidYN="Y">
                <LastName gate:gateId="243">Rasmussen</LastName>
                <ForeName gate:gateId="244">K</ForeName>
                <Initials gate:gateId="245">K</Initials></Investigator>

            <Investigator gate:gateId="246" ValidYN="Y">
                <LastName gate:gateId="247">Tilsted</LastName>
                <ForeName gate:gateId="248">Hans H</ForeName>
                <Initials gate:gateId="249">HH</Initials></Investigator>

            <Investigator gate:gateId="250" ValidYN="Y">
                <LastName gate:gateId="251">Thayssen</LastName>
                <ForeName gate:gateId="252">P</ForeName>
                <Initials gate:gateId="253">P</Initials></Investigator>

            <Investigator gate:gateId="254" ValidYN="Y">
                <LastName gate:gateId="255">Kelbaek</LastName>
                <ForeName gate:gateId="256">H</ForeName>
                <Initials gate:gateId="257">H</Initials></Investigator>

            <Investigator gate:gateId="258" ValidYN="Y">
                <LastName gate:gateId="259">Lassen</LastName>
                <ForeName gate:gateId="260">J F</ForeName>
                <Initials gate:gateId="261">JF</Initials></Investigator>

            <Investigator gate:gateId="262" ValidYN="Y">
                <LastName gate:gateId="263">Thuesen</LastName>
                <ForeName gate:gateId="264">L</ForeName>
                <Initials gate:gateId="265">L</Initials></Investigator></InvestigatorList></MedlineCitation>

    <PubmedData gate:gateId="266">
        <History gate:gateId="267">
            <PubMedPubDate gate:gateId="268" PubStatus="aheadofprint">
                <Year gate:gateId="269">2010</Year>
                <Month gate:gateId="270">3</Month>
                <Day gate:gateId="271">16</Day></PubMedPubDate>

            <PubMedPubDate gate:gateId="272" PubStatus="entrez">
                <Year gate:gateId="273">2010</Year>
                <Month gate:gateId="274">3</Month>
                <Day gate:gateId="275">17</Day>
                <Hour gate:gateId="276">6</Hour>
                <Minute gate:gateId="277">0</Minute></PubMedPubDate>

            <PubMedPubDate gate:gateId="278" PubStatus="pubmed">
                <Year gate:gateId="279">2010</Year>
                <Month gate:gateId="280">3</Month>
                <Day gate:gateId="281">17</Day>
                <Hour gate:gateId="282">6</Hour>
                <Minute gate:gateId="283">0</Minute></PubMedPubDate>

            <PubMedPubDate gate:gateId="284" PubStatus="medline">
                <Year gate:gateId="285">2010</Year>
                <Month gate:gateId="286">5</Month>
                <Day gate:gateId="287">12</Day>
                <Hour gate:gateId="288">6</Hour>
                <Minute gate:gateId="289">0</Minute></PubMedPubDate></History>


        <PublicationStatus gate:gateId="290">ppublish</PublicationStatus>
        <ArticleIdList gate:gateId="291">
            <ArticleId gate:gateId="292" IdType="pii">S0140-6736(10)60208-5</ArticleId>
            <ArticleId gate:gateId="293" IdType="doi">10.1016/S0140-6736(10)60208-5</ArticleId>
            <ArticleId gate:gateId="294" IdType="pubmed">20231034</ArticleId></ArticleIdList></PubmedData></PubmedArticle>

</PubmedArticleSet>
